Mario Sznol, M.D.
Mario Sznol has an international reputation in cancer drug development, a recognized oncology leader whose interests include cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.
Dr. Sznol is currently Professor of Medicine, and Leader, Melanoma/RCC Disease-Associated Research Team at the Yale faculty in medical oncology, which he joined in 2004. He graduated from Rice University in 1979 and from Baylor College of Medicine, Houston, Texas in 1982. He completed internship and medicine residency programs at Baylor College of Medicine, Houston, Texas in 1985. After completing a fellowship in medical oncology at Mount Sinai College of Medicine in NYC in 1987, he joined the NCI as a Senior Investigator in the Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP). He was Head of the Biologics Evaluation Program, IDB, CTEP, from 1994-1999, and in 1999, was appointed to the position of Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, CT.